Mogamulizumab

Drug Profile

Mogamulizumab

Alternative Names: AMG 761; KM8761; KW-0761; Poteligeo

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer Amgen; Bristol-Myers Squibb; Kyowa Hakko Kirin
  • Class Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer
  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 01 Dec 2016 Kyowa Hakko Kirin completes phase-I clinical trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (IV) (NCT02358473)
  • 27 Oct 2016 Phase-II clinical trials in Adult T-cell leukaemia-lymphoma (First-line therapy, Combination therapy) in Japan (IV) (UMIN000022819)
  • 06 Jun 2016 Efficacy and adverse events data from a phase II trial in T-cell Leukemia-Lymphoma presented at 52nd American Society of Clinical Oncology Annual Meeting (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top